Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Januari 2019. De goedkeuring komt eraan in H1-2019 !!!

1.504 Posts
Pagina: «« 1 ... 46 47 48 49 50 ... 76 »» | Laatste | Omlaag ↓
  1. Rotel74 17 januari 2019 15:23
    quote:

    Beowulf1972 schreef op 17 januari 2019 14:59:

    Ik zie het all, Kiadis pompt de koers op zodat ze Pharming kunnen kopen door een plotselinge emissie 1 minuut voor sluiten van de beurs, en de Bilderberg groep is nu met de koers aan het spelen om dat te verhinderen. Obvious.
    Briljant!
  2. [verwijderd] 17 januari 2019 16:20
    Can KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF)’s Tomorrow Be Different? The Stock Had Decline in Shorts
    Posted by Nellie Frank on January 17, 2019 at 2:29 pm

    The stock of KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF) registered a decrease of 6.31% in short interest. KIADF’s total short interest was 89,100 shares in January as published by FINRA. Its down 6.31% from 95,100 shares, reported previously. With 100 shares average volume, it will take short sellers 891 days to cover their KIADF’s short positions.

    It closed at $9.39 lastly. It is up 0.00% since January 17, 2018 and is . It has by 0.00% the S&P500.

    Kiadis Pharma N.V., a clinical stage biopharmaceutical company, focuses on the research and development of cell immunotherapy products for the treatment of blood cancers and inherited blood disorders in the Netherlands. The company has market cap of $253.35 million. The firm focuses on therapeutic indications, including leukaemia, a common form of blood cancer; and thalassemia, an inherited blood disorder. It currently has negative earnings. The Company’s products comprise ATIR101 , a Phase II clinical trial product, which addresses the risk and limitations of hematopoietic stem cell transplantation in blood cancer; and ATIR201, which is in Phase I/II clinical development for inherited blood disorders with an initial focus on thalassemia.

    Another recent and important Kiadis Pharma N.V. (OTCMKTS:KIADF) news was published by Seekingalpha.com which published an article titled: “KIADIS PHARMA N V 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” on April 16, 2018.

    - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
1.504 Posts
Pagina: «« 1 ... 46 47 48 49 50 ... 76 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 876,33 -0,28%
EUR/USD 1,0705 -0,05%
FTSE 100 8.151,53 +0,37%
Germany40^ 17.891,90 -0,22%
Gold spot 2.304,44 +0,82%
NY-Nasdaq Composite 15.605,48 -0,33%

Stijgers

VIVORY...
+7,56%
ForFar...
+6,61%
AMG Cr...
+6,06%
ING
+5,54%
Van La...
+3,60%

Dalers

BAM
-12,78%
ADYEN NV
-2,42%
JUST E...
-2,09%
TKH
-2,02%
ASMI
-1,88%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links